AstraZeneca shares oncology data at ASCO 2023

Betsy Goodfellow | May 25, 2023 | News story | Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology 

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on 2-6 June 2023.

The company plans to share 130 abstracts ‒ featuring 22 approved and potential new medicines across its oncology portfolio and pipeline ‒ with various presentations planned, including one to share overall survival (OS) results from the ADAURA phase 3 trial of Tagrisso (osimertinib) in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Other drugs they will present include Enhertu for a range of advanced HER2-expressing advanced cancers, and Lynparza and Imfinzi in combination to delay progression in newly diagnosed advanced ovarian cancer without a tumour BRCA mutation.

Dave Fredrickson, executive vice president of the Oncology Business Unit at AstraZeneca, commented: “Our unwavering commitment to continually raising the standard of cancer care for patients with high unmet needs is evident in our data at ASCO this year. With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, added: “We are extending the benefits of our practice-changing cancer medicines, including Tagrisso, Imfinzi and Lynparza, while also investing in new scientific platforms such as T-cell engagers and cell therapy to attack cancer from multiple angles and advance the next wave of options for patients. At ASCO, the extraordinary momentum for our antibody drug conjugate (ADC) collaboration portfolio continues with data for Enhertu underscoring its potential across many HER2-expressing tumour types beyond breast, lung and gastric, and updated results for datopotamab deruxtecan that reinforce our confidence in this TROP2-directed treatment.”

Betsy Goodfellow

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer

US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they …

Latest content